Source: Diabetes Care. Unidade: FM
Subjects: DIABTES MELLITUS (COMPLICAÇÕES), FÁRMACOS DO SANGUE E SISTEMA HEMATOPOÉTICO, INIBIDORES DE ENZIMAS, NEOPLASIAS (ETIOLOGIA)
A citação é gerada automaticamente e pode não estar totalmente de acordo com as normas
ABNT
UDELL, Jacob A. et al. Saxagliptin and Cardiovascular Outcomes in Patients With Type 2 Diabetes and Moderate or Severe Renal Impairment: Observations From the SAVOR-TIMI 53 Trial. Diabetes Care, v. 38, n. 4, p. 696-705, 2015Tradução . . Disponível em: https://doi.org/10.2337/dc14-1850. Acesso em: 01 nov. 2024.APA
Udell, J. A., Bhatt, D. L., Braunwald, E., Cavender, M. A., Mosenzon, O., Steg, G., et al. (2015). Saxagliptin and Cardiovascular Outcomes in Patients With Type 2 Diabetes and Moderate or Severe Renal Impairment: Observations From the SAVOR-TIMI 53 Trial. Diabetes Care, 38( 4), 696-705. doi:10.2337/dc14-1850NLM
Udell JA, Bhatt DL, Braunwald E, Cavender MA, Mosenzon O, Steg G, Davidson JA, Nicolau JC, Corbalan R, Hirshberg B, Frederich R, Im KA, Umez-Eronini AA, He P, McGuire DK, Leiter LA, Raz I, Scirica BM. Saxagliptin and Cardiovascular Outcomes in Patients With Type 2 Diabetes and Moderate or Severe Renal Impairment: Observations From the SAVOR-TIMI 53 Trial [Internet]. Diabetes Care. 2015 ; 38( 4): 696-705.[citado 2024 nov. 01 ] Available from: https://doi.org/10.2337/dc14-1850Vancouver
Udell JA, Bhatt DL, Braunwald E, Cavender MA, Mosenzon O, Steg G, Davidson JA, Nicolau JC, Corbalan R, Hirshberg B, Frederich R, Im KA, Umez-Eronini AA, He P, McGuire DK, Leiter LA, Raz I, Scirica BM. Saxagliptin and Cardiovascular Outcomes in Patients With Type 2 Diabetes and Moderate or Severe Renal Impairment: Observations From the SAVOR-TIMI 53 Trial [Internet]. Diabetes Care. 2015 ; 38( 4): 696-705.[citado 2024 nov. 01 ] Available from: https://doi.org/10.2337/dc14-1850
